CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

203565Orig1s000

Trade Name: INJECTAFER

Generic Name: ferric carboxymaltose injection

Sponsor: Luitpold Pharmaceuticals, Inc.

Approval Date: January 17, 2013

Indications: Injectafer (ferric carboxymaltose injection) as an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron;
- who have non-dialysis dependent chronic kidney disease.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

CENTER FOR DRUG EVALUATION AND RESEARCH

203565Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Summary Review	**X**
Officer/Employee List	**X**
Office Director Memo	
Cross Discipline Team Leader Review	**X**
Medical Review(s)	**X**
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	**X**
Statistical Review(s)	**X**
Microbiology Review(s)	**X**
Clinical Pharmacology/Biopharmaceutics Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203565Orig1s000

APPROVAL LETTER

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203565

NDA APPROVAL

Luitpold Pharmaceuticals, Inc.
Attention: Marsha E. Simon
Sr. Manager, Regulatory Affairs
800 Adams Avenue, Suite 100
Norristown, PA 19403

Dear Ms. Simon:

Please refer to your New Drug Application (NDA) dated September 30, 2011, received October 3, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for INJECTAFER (ferric carboxymaltose injection).

We acknowledge receipt of your amendments dated November 15; December 5 and 13, 2011; January 6 and 11; February 8; March 26; April 13, 23, 24, and 27; May 16; June 6 and 25; July 18; September 13; October 29; and December 5, 2012; January 30; February 5; March 13 and 20; April 2 and 12; May 6 and 31; June 13; and July 2, 16 (2), 17, 19, 22 (2) and 24, 2013.

The January 30, 2013, submission constituted a complete response to our July 23, 2012, action letter.

This new drug application provides for the use of INJECTAFER (ferric carboxymaltose injection) as an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron;
- who have non-dialysis dependent chronic kidney disease.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

We acknowledge your July 22, 2013, submission containing final printed carton and container labels.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and immediate-container labels that are identical to the carton and immediate-container labels submitted on July 22, 2013, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 203565**." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ADVISORY COMMITTEE

Your application for INJECTAFER (ferric carboxymaltose injection) was not referred to an FDA advisory committee because this drug is not the first in its class, the safety profile is similar to that of other drugs approved for this indication, and the application did not raise significant safety or efficacy issues that were unexpected for a drug/biologic of this class.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.